Where this information about bisphosphonates comes from

This page tells you about the major sources of information that we use to put together this section of CancerHelp UK.

All our information is checked by cancer specialists. The names of our specialist reviewers are at the end of this list. We also try to find patients to review all our sections. If you have had bisphosphonates, live in the UK and would like to become a patient reviewer, you can write to us by clicking on the 'contact us' button on the right hand side of this page.

Websites

Electronic Medicines Compendium
www.medicines.org.uk

British National Formulary
www.bnf.org

National Institute of Clinical Excellence Guidelines
www.nice.org.uk

Scottish Intercollegiate Guidelines Network
www.sign.ac.uk

National Cancer Institute - USA
www.cancer.gov

PubMed Central - National Institute of Health Medical Archive of Science Literature
www.pubmedcentral.nih.gov

Books

Handbook of Cancer Chemotherapy (7th edition)
Keel, Roland K.
Lippincott Williams and Wilkins, 2007.

Principles and practice of oncology (8th edition)
De Vita, V.T., Hellman, S. and Rosenberg S.A.
Lippincott, Williams and Wilkins, 2008.

Reviews and articles

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Michael Pazianas, Cyrus Cooper, F Hal Ebetino, R Graham G Russell. Therapeutics and Clinical Risk Management
2010:6 325–343

Bisphosphonates in multiple myeloma. (Cochrane review). R Mhaskar, J Redzepovic, K Wheatley, OAC Clark, B Miladinovic, A Glasmacher, A Kumar, B Djulbegovic B. Database of Systematic Reviews 2010, Issue 3. Art. No.: CD003188. DOI: 10.1002/14651858.CD003188.

Emerging role of bisphosphonates in the clinic - antitumor activity and prevention of metastasis to bone. Lipton A. Cancer Treatment Review. 2008;34 Suppl 1:S25-30.

Zoledronic acid in the management of metastatic bone disease. Polascik TJ, Mouraviev V. Therapeutic Clinical Risk Managagement. 2008 Feb;4(1):261-8.

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Cancer. 2008 Jul 1;113(1):193-201.

Bisphosphonates for breast cancer. (Cochrane review). N Pavlakis, RL Schmidt, M Stockler. Database of Systematic Reviews 2007, Issue 1. Art. No.: CD003474. DOI: 10.1002/14651858.

Bisphosphonates for advanced prostate cancer. (Cochrane review). KK Yuen, M Shelley, WM Sze, TJ Wilt, M Mason. Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006250. DOI: 10.1002/14651858.CD006250.

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Migliorati Prof. Cesar A, Siegel Prof Michael A, and Elting Prof Linda S. Lancet Oncology, Volume 7, Issue 6, June 2006, Pages 508-514.

Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Costa L, Lipton A, Coleman RE. Supportive Cancer Therapy. 2006 Apr 1;3(3):143-53.